Study to Evaluate the Safety and Effectiveness of Localizing Biopsy-Proven Metastatic Axillary Lymph Nodes in Women with Breast Cancer Using Magseed Markers as an Alternative to the Current Practice of Placing Radioactive Seed Markers

Overview

About this study

The purpose of this study is to evaluate if Magseed is a viable alternative to radioactive seed as a localization method for biopsy proven metastatic breast carcinoma following neoadjuvant chemotherapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Women 18 years or older
Neoadjuvant chemotherapy planned prior to surgical excision
Scheduled for target axillary lymph node dissection including the localized lymph node and sentinel lymph node

Exclusion Criteria:

Pregnant or nursing women
Allergy to lidocaine or gadolinium
Contraindication to MRI (i.e. pacemaker)
Axillary Infection
Prior axillary radiation

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Genevieve Woodard, M.D., Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Genevieve Woodard, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials